State Treasurer State of Michigan held its stake in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 25,000 shares of the biotechnology company’s stock at the end of the first quarter. State Treasurer State of Michigan’s holdings in Aurinia Pharmaceuticals were worth $184,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of the company. OTA Financial Group L.P. bought a new stake in Aurinia Pharmaceuticals during the first quarter valued at approximately $1,291,000. Hikari Power Ltd bought a new stake in shares of Aurinia Pharmaceuticals during the first quarter worth approximately $440,000. Candriam Luxembourg S.C.A. bought a new stake in shares of Aurinia Pharmaceuticals during the first quarter worth approximately $866,000. Acuta Capital Partners LLC bought a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter worth approximately $2,100,000. Finally, Oxford Asset Management bought a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter worth approximately $211,000. 29.26% of the stock is owned by hedge funds and other institutional investors.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings data on Monday, May 15th. The biotechnology company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.08. The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.05 million. Aurinia Pharmaceuticals had a negative return on equity of 50.53% and a negative net margin of 48,278.23%.
TRADEMARK VIOLATION NOTICE: “State Treasurer State of Michigan Maintains Position in Aurinia Pharmaceuticals Inc (AUPH)” was originally posted by BBNS and is owned by of BBNS. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://baseballnewssource.com/markets/state-treasurer-state-of-michigan-has-184000-stake-in-aurinia-pharmaceuticals-inc-auph-updated-updated/862811.html.
A number of analysts have recently commented on AUPH shares. FBR & Co reiterated an “outperform” rating and issued a $9.00 price target on shares of Aurinia Pharmaceuticals in a research note on Tuesday, March 14th. Leerink Swann raised their price objective on shares of Aurinia Pharmaceuticals from $7.00 to $11.00 and gave the stock an “outperform” rating in a report on Thursday, March 2nd. Zacks Investment Research downgraded shares of Aurinia Pharmaceuticals from a “buy” rating to a “sell” rating in a report on Tuesday, March 7th. Canaccord Genuity reissued a “buy” rating and issued a $10.00 price objective on shares of Aurinia Pharmaceuticals in a report on Friday, March 3rd. Finally, HC Wainwright lifted their price target on shares of Aurinia Pharmaceuticals from $8.00 to $12.00 and gave the company a “positive” rating in a report on Friday, March 3rd. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $9.64.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with our FREE daily email newsletter.